A clinical-stage company focusing on immuno-oncology and autoimmune conditions with therapies that modulate T cell responses.
Georgiamune is developing novel immune checkpoint blockades to address the needs of cancer patients that do not benefit from first-generation checkpoint inhibitors, such as Merck's Keytruda. Additionally, Georgiamune is developing oral small molecule specific regulatory T cell activators and inhibitors that address the underlying pathology that drives the progression of various cancers and/or autoimmune disorders.
Georgiamune is developing novel immune checkpoint blockades to address the needs of cancer patients that do not benefit from first-generation checkpoint inhibitors, such as Merck's Keytruda. Additionally, Georgiamune is developing oral small molecule specific regulatory T cell activators and inhibitors that address the underlying pathology that drives the progression of various cancers and/or autoimmune disorders.
Total raised: $75M
Investors 2
| Date | Name | Website |
| 26.10.2023 | Catalio Ca... | cataliocap... |
| 09.02.2024 | Hawktail M... | hawktail.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.08.2023 | Series A | $75M | BioVenture... |
Mentions in press and media 6
| Date | Title | Description |
| 14.01.2025 | Healing Horizons: Georgiamune Founder Dr. Samir Khleif Aims to Unlock the Full Potential of Cancer Immunotherapy Born in the US, and aided by the support of the Qatar Foundation's Arab Global Scholars... | "The idea at the time was: is it possible to develop therapies that employ our immune systems to fight cancer?" recalls Dr. Samir Khleif when speaking about his time at the US-based National Cancer Institute (NCI)- a tenure that w... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 18.08.2023 | Georgiamune: Clinical-Stage Biotechnology Company Closes $75 Million In Funding | Georgiamune – a privately held clinical-stage biotechnology company – recently announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclon... |
| 16.08.2023 | DC Money Moves: ASRC Federal subsidiary secures an $8B contract from NOAA | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at dc@technical.ly. Reston-based ASRC Federal subsidiary Data Networks, secured a spot on a National Oceanic and Atmospheric... |
| 09.08.2023 | Georgiamune Closes $75M Series A Financing | Georgiamune Inc., a Gaithersburg, Md.-based clinical stage biotechnology company working in the fields of oncology and autoimmune diseases, completed a $75M Series A financing. General Catalyst and Parker Institute for Cancer Immunotherapy ... |
| - | Georgiamune | “Regulating signaling pathways to restore immune homeostasis to fight cancer and autoimmune diseases.” |